CEU Role of Human Papilloma Virus Testing in Cervical Cancer Prevention


  • Molly C. Fey FNP, MSN,

    Corresponding authorSearch for more papers by this author
    • Molly C. Fey, FNP-C, MSN, is a graduate of Yale University School of Nursing. She practices at the Bridgeport Hospital Pediatric Primary Care Center in Bridgeport, Connecticut.

  • Margaret W. Beal CNM, PhD

    Search for more papers by this author
    • Margaret W. Beal, CNM, PhD, is an Associate Professor and Director of the Graduate Entry Prespecialty in Nursing at Yale University School of Nursing, where she teaches nursing and midwifery students. She practices with Planned Parenthood of Connecticut.

Molly C. Fey, FNP, MSN, P.O. Box 1338, New Haven, CT 06505. E-mail: mollyfey@hotmail.com


A clear causal relationship has been established between human papilloma virus (HPV) infection and the development of cervical cancer. Genital HPV infection is currently the most common sexually transmitted disease worldwide. The recent 2001 American Society for Colposcopy and Cervical Pathology Consensus Guidelines have included HPV testing for management of women with cervical cytological abnormalities. Clinicians now face the challenge of deciding when to use HPV testing in follow-up of abnormal Pap tests. This article includes updates on HPV, cervical cancer screening, and HPV testing technology. Recommendations for integration of HPV testing into clinical practice are provided.